quarter high XX%. quarter everyone. and over pleased more by a year Good new exceptionally margin grew than revenue product gross revenue Stephanie. the tripled an of XXXX for you, to report I strong XX% very Product impressive Codexis. reached for Total year-over-year. results second afternoon, a Thank am ago,
are model, revenue. impressive on contributed capitalize groundwork whom in quarter, $X rapidly Codexis' business had efforts our We line revenue $XXX,XXX over into XX the who demonstrating in top We of accelerating over years contributed R&D translating of X million growth. ability in to and customers
food solidified as have that customer sector, in executed manufacturing, the with innovative to applications. beverage commercialization more they order. guidance million delivery raising XXXX of working the later executed revenue solid help call. will to them exceptional have late-stage top our we on again, in significant details pharma agreement hop are commercial-scale from business. in an quantity sales of our use will process. a and enzymes. clinical of This the In in designed received We global $XX.X for Codexis' for process product regulatory June, therapeutic business manufacturing drug accelerated cylinders upon sustainable history. for we that in This our all June, a We company's one annual the receipt XXXX we On be Kalsec, we additional an proprietary are manufacturing extracts order's Ross largest needs new unnamed firing from the is pharmaceutical is company enzyme introduce development in provide a as raised with within the the that of that product our trials deliver order partner, guidance recently well. significant have a schedule and Today, new indications strength to in in
business, and products of revenue newly to pipeline. a nutrition life to commercial the to and to of our our our momentum sweeteners, significant very related outlook In interest, partnered for solid Tate and in the & over year. their exercised programs a vertical. XXXX building stevia both the partner, program we and traction launched our these had for R&D also to We're Biotherapeutics Takeda, enzymes option balance the add gain the drive to sales to science expand good collaboration strong continue Lyle our And We market revenues continued allulose have tools fourth market, engineered with its in growth. food
our number programs, to addition business. resources R&D of applying we programs are the all self-funded all an to of of our customer-driven In lines across increasing
at XXXX, number company, as see IR our advancing pipeline we XX, our them are of growth in on further website. to to provide how find part as our we're you an across future. pipeline We programs strategy capture Every of June, of ways value opportunities. and future snapshot into of the a products even and provide breaking we development to can this here insight annual down of expanding update Today, our greater the which end June year, in programs published the on
Let me few are think a metrics I highlight particularly that salient.
total XX increasing to number XX. pipeline our and products XX% commercial year, First, from grown has by since of programs last
our XX XX area growth from We XX% have Note manufacturing more but Pharma stakes in X up The on of to commercial to to revenue goal drive be broadly. pharma science manufacturing enzyme food growth delivering and XX% markets pipeline, life performance to industrial sector, well. are in recurring as dramatically the nice versus also outside manufacture here. other product increased ago. continues growth we're the momentum tools putting We than our the programs our we last application in for year, it's led of in XXXX is the in the stage, the so also but enzymes more in by building ground now the the past. largest ultimate see sustainably to Clearly, great commercial dramatic number is us this goal. pipeline programs years just revenue products, connected sell shots to
last license well, three in Codexis to and new its continues programs expand the by the option as pipeline over year self-funded Takeda's during our of biotherapeutics the investments from exercise program by highlighted fourth Our quarter. to
verticals over all our advancing new goal, explosion high-growth and Tools more speed programs Biotherapeutics. X is as peak the Science you an Slide in those doubling the these forward, in market X-year pipeline, increasing to in in see towards in forward potential, Novel model commercial, acceleration continuing program on our We than can almost -- look to tandem. business shots of Our delivering to shown of of adding assets consistently the our and in years trends X, revenue average trends going Life all to categories,
usage, market Let's past dive more which and enzymes and lower higher currently using be their the represents molecule the our needs customers end deeply products. our speed the continue meaningfully, company's And manufacturing of decrease sustainable nonenzymatic Small pharmaceutical sustainability been continue across X novel Codexis' while our the is of enzymes inefficient, to our the enable revenues. decades, value-creating constantly of dramatically traditional our chemistry, into reduce high-performance where Sustainable capital-intensive majority enzymes. with large recent have increase ability manufacturing cost leadership to to is and Compared enabling core to platform for and design reduced enzyme processes is starting to engineering our Codexis. built energy also sustainable yields, businesses, waste growing and manufacturing progress Codexis' generation. over manufacturing. discover and the CodeEvolver accelerating target a engineered this X these for market capital we
the XXXX, to we announced scale install and to order with top adopt XX to we've of this kilograms, manufacturing help partnered up APIs. June of already months, historic a the chain speed. additional enzymes fully the supply will matter in a for able now produce scaled sufficient to pharmaceutical in The to we global capacity fulfill we customer company from second this to $XX.X metric one strong Codexis fruition is fulfill manufacture order during on and it in pharmaceutical mentioned established and June the of novel that to earlier, Codexis, largest are for XXXX. undisclosed unprecedented half indications they as and up incremental In the position them we from the of hundreds of an be supply production enzyme came the need ramped that order, have demand. have ton And their and already at of with I We companies XX in world million
CodeEvolver business undisclosed, patented, the using sustainable GlaxoSmithKline. an engineered back-end process to milestone drug. are our commercialization the back-end GSK XXX% on-the-market of protein the another to payment ability by our was In It that by business partner, is a of to designed improve our from model. our aspect milestone for engineering our manufacturing and the is payments to key highlighting profit licensed largest [Technical in enzyme this an Another partners. related asset second CodeEvolver licensing one manufacturing step earned Difficulty] margin, we as platform technology CodeEvolver such license quarter,
incredibly in-house, collaboration customer but was to platform also announced one transfer license proud to technology to transfer portion [Technical Difficulty] where transfer. first smooth bring the technology of implement efforts third had ensure a of to to Novartis our tech the CodeEvolver a I'm with of enable team's licensing considerable completion our operate to the Novartis. tech we a This a We in lockstep virtually.
addition ingredients, of industries, to We're about the years, including et other in feed, our hot designing a an into also enzymes the been manufacturing consistent to pharma In produce and applications, agreement to for efficiency, to for and newest nutrition development beverage support we in care, functionality, past while expanding natural This and partnership, animal cetera. food manufacturing, we've mission was and deliver few to range sustainably recycling, hop food growing stability, taste, industry enabling of and novel shorter collaboration have development the Through to market announced products. exclusive Kalsec, of our excited a improve and reach beverage vertical. enzyme leading furthering Kalsec's our products. engineered more really we timelines a with characteristics enzyme enzymes opportunities of sustainable Kalsec quickly. and Recently, producer expansion entered extract. supply lower regulatory CodeEvolver and products research the technology hurdles, using to clean-label have These enabling Codexis' our the the food consumer
of and with shift continue faster-to-market Allulose also encouraging late-stage candidates, & quarterly of progress Kalsec, enzymes these This PRIMA could very in development for time. is and downstream industrial In strong the adoption one other this to sweeteners use M that the for of enzyme had deep product to over products Tate growth to addition Codexis' and a our enzymes, DOLCIA our products the newest believe pipeline sustainable Lyle. expect manufacturing. from new growing be sales are we grow to high-margin, With sweeteners. towards accelerate we enzyme they manufacturing Sevia They largest the and growing Tasteva sales their of development we
above-average the to and The for biosensor molecular more. market RNA be multiple high and very Another This applications, us in life the prospects. next-generation market, DNA that Codexis' enzymes past we and the Transcriptase. sequencing in addition opportunity margin customers, for its In area rapid we've is enzymes broad-based Codex is which to of science marketed engineered improvements Codexis significant growth Codex company. can enable the synthesis, three diagnostics, enzymes develop also RNA marketing, expansion can engineered Reverse affords given HiFi commercialization products opportunity developed market for and year, a is and new cycles, tools science attractive, growth, polymerase, HiCap partners. life customize Codex DNA highly to polymerase, for customer the tools
we the In already Our half use. and advance XXXX, end the demonstrating as RNA way success. XXXX. dramatically the amount stabilizing HiCap last the and efficiency, of year that reagent commercialization to product enzymes marketing of we've DNA to capping these for began enabling towards polymerases Codex capping RNA customers have critical the at significantly provide led is first of reduce pharmaceutical polymerase to been engineered We rapidly higher
with first messenger our messenger In of and double-stranded unwanted Codex earlier sales of of impurities, several year, now and HiCap commercial RNA polymerase product. yield increases is purification enzyme the other production proprietary in customer stages to RNA trials of We decreases simplifies this downstream manufacturers. product our made the various customers this addition, RNA which multiple
processes installations Although a are cycle a we positioned and and of had mRNA-based hoped, bit start, for longer an is the confident therapeutic development-stage candidates. for range adoption in this we potential excellent vaccines that is than well we're
meaningfully more HiFi Codex also the DNA progress We launch expect of coming making quarters. grow We're with the in sales to product begin polymerase. to solid
in polymerases their this both Our potential progress Transcriptase has in year. launch further performance early in tested. the sequencing highest demonstrates Codex Reverse applications. being current developed are high-profile tested and and polymerase and enzymes versus a to been trials access by sequencing Codex and is sampled our kits, users, enzyme customers analysis future fidelity results dozens HiFi of is of next-gen is later currently for that preparing being NGS all incumbent their encouraging. improve competitive DNA for diagnostic we use DNA broader It The by enables the
enzyme tools we leader marketed on life products applications. as an these developing with the for new In parallel quarter, second science a science advancing customer-partnered earned addition in revenue-generating unnamed In programs have are an milestone we life broadly enzyme multiple option well. also partnered to tools and products,
Codexis high-value DNA. on Assemblies As we synthesis, synthesizing Molecular complete an second half program an with range collaboration project. of in tools differentiated and should the Codexis update progress on and on continues increasing viable, from manufacturing biology, potential term, data enthusiastic CodeEvolver the remain commercially dramatic the significantly we of for development markets, momentum highly performance With to strong longer strong of of number to power make of long-chain to life work to has We discovery technical approach with for and value-creating continue discovery in storage. on XXXX. enzyme about market, enzymes impact partnerships a capitalize potential the deliver this the make the we opportunity. that process biotherapeutics. silicon to the novel remain business commercialization Molecular for enzymatic through our DNA to wrapping engineering groundbreaking the disruptive and are manufacturing drug compete this solution improvements, science and to to track synthetic in engineering Leveraging for up of a This differentiated Assemblies' review, the wide In products high-growth cost-effective, this DNA
and therapy candidates using biologics discovered a Here, of platform. high-value oral rapidly pipeline building our CodeEvolver and gene we advancing are
programs one stage and and a we including to enablement early-stage years our today, had in pipeline. a in development. Fast in ago, over another Just two very dozen programs only have forward the few IND we clinical pipeline, in
rare with Pharmaceuticals for improving We focused candidates multiprogram gene Takeda impressive have an therapy on partnership diseases.
expression, as stability, we transgenes enhanced such to with uptake leveraging are half-life, improved engineer CodeEvolver better Here, improved cells. greater and attributes, difficult-to-access in
bringing expand number quarter, for an our of the its exercised disorder, option agreement to under for and additional lysosomal total to the the second Takeda a the development programs During research gene four. therapy strategic storage collaboration of
better-performing are improved discovery Codexis. blood extremely and Leveraging CodeEvolver the differentiated indication with potential Pompe discover for proud using have oral a to a expression is disease, and rare enable therapies transgenes high-value after another Takeda. therapy and and have to disorders. year treatment Modifying programs its rare to given CodeEvolver deficiency are design-improved programs diseases. embarked factor that self-funded gene targeting addition we with are strategy on therapy's is in discover of that stable, we we Accordingly, of partnered gastrointestinal success the in in biologics Fabry to for for efficacious gene transgenes generated undisclosed novel to We just Especially the collaboration safe, disease, indications with for an novel more growth a other enthusiasm is just of of patients our gene Takeda, candidates. partnership, approach a for Takeda's enzyme expansion a four next-generation year genetic therapies for into the gene technology gratifying to differentiated this X ability
Health X have in the programs We targeting the self-funded undisclosed with the biologics partnered is Nestle most GI and early-stage, which partnership are those Nestle advanced CDX-XXXX, co-owned Three of disorder. programs. being oral an Science between with X of parties,
now have been CDX-XXXX, activities preclinical IND-enabling successfully for GMP and toxicology, including manufacturing Our completed.
has regulatory CDX-XXXX been authorities clinical the approvals for of year. expect for to initiate States which turn filed the the with addition, first In we its around trial, ex-United
you to Now through detail. Ross our more in call to results over let me hand financial take the
